Biocytogen, a biomedical contract research organization (CRO) specialized in gene-targeted animal models and services, announced on Thursday that it has raised RMB543 million (US$77.11 million) in a series D round of financing. The series D round was led by China Life Healthcare Fund, a healthcare private equity fund of state-owned insurance conglomerate China Life, and […]

Chinese Biomedical CRO Biocytogen Raises $77M In Series D Round comes originally from China Money Network. All Rights Reserved.